louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01866189: Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
Official title: Assessment of Hypoxic Tissues in Acute Ischemic Stroke With 18F-FMISOnidazole PET and Comparison With MRI : A Prospective Multicenter Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Ischemic Stroke
Keywords: ischemic stroke
hypoxic tissues
F-MISO uptake
Magnetic Resonance Imaging
F-MISO Positon Emission Tomography
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2013-05-31
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is a French multicenter prospective study including 5 stroke units with available MRI and F-MISO PET for patients with acute ischemic stroke.

Background and Purpose: 18F-Fluoromisonidazole (FMISO) PET has been used to identify hypoxic tissues in animals and stroke patients. While MRI has become the gold standard acute stroke imaging, no published study has compared FMISO PET and MRI.

The aim of this prospective study is to identify hypoxic tissues in 40 patients with acute ischemic stroke with F-MISO PET and to compare the location and the outcome of these hypoxic cells with MRI datas (weighted diffusion and FLAIR) and to clinical outcome.

Detailed description: 40 prospective patients (aged 18 to 85 years) will be included in the first 36 hours after ischemic stroke onset.

The study period will be 2 years. Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.

The aim of the study is to locate hypoxic tissues and to compare with ischemic tissues defined by diffusion and FLAIR MRI sequences, with MRI evolution, and with clinical status at day 7 and day 90.

Inclusion criterias

* Patients aged 18-85 years with encephalic brain ischemic stroke,
* defined stroke onset,
* NIHSS 5 to 20,
* F-MISO Pet and MRI available \<36 hours after stroke onset,

Eligibility criteria: Inclusion Criteria:

* Patients aged 18-85 years with encephalic brain ischemic stroke,
* defined stroke onset,
* NIHSS 5 to 20,
* F-MISO Pet and MRI available \<36 hours after stroke onset,
* Written consent signed by patient or family

Exclusion Criteria:

* contraindication to MRI
* comatous status
* 5 \< NIHSS \> 20
* non ischemic stroke
* brainstem stroke

Primary outcomes:
measure: volume and location of F-MISO uptake in stroke patients
timeFrame: acute phase of brain ischemia < 36 hours
Secondary outcomes:
measure: comparison of F-MISO uptake areas and ischemic lesions defined by weighted diffusion and FLAIR on
timeFrame: acute phase of brain ischemia < 36 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02547389: Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy
Official title: Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epilepsy
Lead sponsor: NMP Medical Research Institute
Sponsor class: OTHER
Collaborators: name: Macmillan Research Group UK
First posted: 2015-09-11
Enrollment: 144
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Improving medical compliance and health-related quality of life (HRQoL) among people with epilepsy (PWE) has become the focus of various treatment programs and behavioral interventions which continue to be challenging to both patients and health care professionals.

In order to design an effective intervention on the management of epilepsy, the drug management of epilepsy by community health workers was evaluated.


Eligibility criteria: Inclusion Criteria:

* Eligible participants must have a definitive diagnosis of epilepsy for at least 6 months, based on the clinical judgement of the investigators. Epilepsy is defined by two or more unprovoked seizures. Clinical history, electroencephalography, and imaging data are all instrumental in rendering a formal decision. The seizure type, frequency, or severity are not criteria for exclusion, although this information will be recorded.
* Patients must have a seizure frequency of at least two seizures in a 6 month period of time.
* Patients must be on at least one anti-epileptic medication.
* Patients must be able to report seizure frequency with either a paper or electronic diary.
* Patients must be able to read and understand either English or Hindi.
* Patients must be able to complete questionnaires and provide informed consent to this study.

Exclusion Criteria:

* A diagnosis of psychogenic nonepileptic seizures
* Severe depression, anxiety, or psychosis
* Recent problem with substance abuse.

Primary outcomes:
measure: Compliance with taking prescribed medications
timeFrame: 12 months
Secondary outcomes:
measure: Seizure frequency per month
timeFrame: change from baseline to 12 months in number of seizures per month assessed by patients diary
measure: Quality of Life (Malay Quality of Life in Epilepsy Inventory-30)
timeFrame: change from baseline to 12 months in quality of life assessed by Malay Quality of Life in Epilepsy Inventory-30
Other outcomes:
Locations:
Study officials:
affiliation: NMP Medical Research Institute
name: Hitesh K Nayak
role: PRINCIPAL_INVESTIGATOR
affiliation: Macmillan Research Group UK
name: Neha Sharma, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03345589: A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis
Official title: A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Primary Biliary Cholangitis
Keywords: Ursodeoxycholic Acid
Lead sponsor: West China Hospital
Sponsor class: OTHER
First posted: 2017-11-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the effect of 18-22mg/kg/d Ursodeoxycholic in refractory Primary Biliary Cholangitis


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with primary biliary cholangitis
* Treated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid

Exclusion Criteria:

* Autoimmune hepatitis
* Primary sclerosing cholangitis

Primary outcomes:
measure: Percent of patients that achieve biochemical remission of primary biliary cholangitis(PBC)
timeFrame: Month 6 during treatment with 13-15mg/kg/d ursodeoxycholic acid or 18-22mg/kg/d ursodeoxycholic acid
Secondary outcomes:
measure: Alkaline phosphatase
timeFrame: Week 2 and Month 1, 3, 6,9,12
measure: Glutamyltransferase
timeFrame: Week 2 and Month 1, 3, 6,9,12
measure: Alanine transaminase
timeFrame: Week 2 and Month 1, 3, 6
measure: Aspartate transaminase
timeFrame: Week 2 and Month 1, 3, 6, 9,12
measure: Total bilirubin
timeFrame: Week 2 and Month 1, 3, 6, 9,12
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital
state: Sichuan
Study officials:
affiliation: West China Hospital
name: Li Yang, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04839289: Hearing Aid Signal Processing Comparative Study
Official title: A Study to Compare Patient Perceptions of Two Different Hearing Aid Signal Processing Philosophies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss, Sensorineural
Lead sponsor: Sonova AG
Sponsor class: INDUSTRY
First posted: 2021-04-09
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Participants will be fit with each of two hearing instruments in an ABA cross-over design. The study will consist of a total of three approximately 10-day home trials with the devices. Participants will be asked to provide qualitative feedback to investigators regarding the performance of and their preference for each hearing instrument.


Eligibility criteria: Inclusion Criteria:

* Moderate to severe sensorineural hearing loss
* Current hearing aid user

Exclusion Criteria:

* Lack of willingness to wear study devices for approximately one month
* Inability to travel to study appointments or to complete questionnaires.

Primary outcomes:
measure: Standardized Validated Questionnaire Measuring Hearing Aid Sound Quality for First Study Set Worn, i.e. Study Set A for Arm A-B-A and Study Set B for Arm B-A-B
timeFrame: End of home trial 1 (Day 10 of study)
measure: Standardized Validated Questionnaire Measuring Hearing Aid Sound Quality for Second Study Set Worn, i.e. Study Set B for Arm A-B-A and Study Set A for Arm B-A-B
timeFrame: End of home trial 2 (20 days after study start)
measure: Standardized Validated Questionnaire Measuring Hearing Aid Sound Quality for Third Study Set Worn, i.e. Study Set A for Arm A-B-A and Study Set B for Arm B-A-B
timeFrame: End of home trial 3 (30 days after study start)
measure: Standard Validated Questionnaire Measuring Satisfaction of Hearing Aid Performance and Features for First Study Set Worn.
timeFrame: End of home trial 1 (Day 10 of study)
measure: Standard Validated Questionnaire Measuring Satisfaction of Hearing Aid Performance and Features for Second Study Set Worn.
timeFrame: End of home trial 2 (Day 20 of study)
measure: Standard Validated Questionnaire Measuring Satisfaction of Hearing Aid Performance and Features for Third Study Set Worn.
timeFrame: End of home trial 3 (Day 30 of study)
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Phonak Audiology Research Center
state: Illinois
Study officials:
References:
Clinical trial NCT01706289: The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy
Official title: The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neuropathy; Peripheral, Autonomic, in Diabetes Mellitus (Manifestation)
Keywords: diabetes
cardiovascular autonomic neuropathy
VAP 1
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2012-10-15
Enrollment: 150
Sex: ALL
Minimum age (years): 10
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: type 2 diabetes mellitus

Brief summary: Exploring the relationship between serum VAP-1 and cardiovascular autonomic neuropathy in subjects with type 2 diabetes mellitus

Detailed description: The prevalence of diabetes mellitus is increasing recently, especially in the urban area of developing countries. Subjects with diabetes have higher rate of hospitalization and have higher mortality. Diabetes results in various complications including diabetic retinopathy, nephropathy, neuropathy, and cardiovascular complications. Among these, cardiovascular autonomic neuropathy is one of clinical important complication of diabetes. Diabetic subjects with reduced cardiovascular autonomic function have been shown to strongly associate with an increased risk of silent myocardial ischemia and increased mortality. They also have higher risk of sudden death, intraoperative and perioperative cardiovascular instability. Formation of advanced glycation end product (AGE) and oxidative stress are important causes of diabetic neuropathy. Vascular adhesion protein-1 (VAP-1), an adhesion molecule with an activity of semicarbazide-sensitive amine oxidases (SSAO), which can catalyze endogenous amines to produces corresponding aldehydes, H2O2, and ammonia. We have demonstrated that serum VAP-1 is a source of systemic AGE and oxidative stress, and is associated with nephropathy and atherosclerosis. There are reports demonstrating that subjects with diabetic retinopathy or stroke have higher serum VAP-1. To our best knowledge, there is no report regarding the relationship between serum VAP-1 and neuropathy. In present study, we will measure serum VAP-1 and check cardiovascular autonomic function. We will also explore the relationship between serum VAP-1 and cardiovascular autonomic neuropathy in subjects with type 2 diabetes mellitus.

Eligibility criteria: Inclusion Criteria:

* type 2 diabetes mellitus

Exclusion Criteria:

* arrythmia

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Yun Lin
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Hung-Yaun Li
role: STUDY_CHAIR
References:
Clinical trial NCT06524089: Pilates Versus Eccentric Exercises on Multiple Sclerosis
Official title: Pilates Versus Eccentric Exercises in Chronic Low Back Pain With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Keywords: Pilates
eccentric
multiple sclerosis
low back pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-07-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel group prospective randomized clinical trial
Primary purpose: TREATMENT

Brief summary: This study aims to determine whether Pilates-based stability or eccentric training is more effective for patients with multiple sclerosis(MS) with chronic non-specific low back pain(NSLBP).

Detailed description: Thirty adult patients with multiple sclerosis with chronic NSLBP verified diagnosis of MS by a specialized neurologist will be questioned and screened according to inclusion and exclusion criteria.

Patients were randomly allocated to one of two groups: (Pilates or Eccentric). Every individual in both groups will be examined before and after the 6-week treatment program.

The handheld dynamometer assessed isometric trunk flexion and extension strength Pain intensity by casual analog scale (VAS). The Trunk Impairment Scale (TIS) evaluates static and dynamic sitting balance and trunk coordination in a seated position.

Eligibility criteria: Inclusion Criteria:

* Age range 18 to 40 years.
* Relapsing-remitting free for at least 90 days before testing.

Exclusion Criteria:

* Having a neurologic disease other than MS.
* A relapse within 3 months.

Primary outcomes:
measure: pain intensity
timeFrame: At baseline and after 6 week
measure: Function
timeFrame: At baseline and after 6 week
Secondary outcomes:
measure: back muscle strength
timeFrame: At baseline and after 6 week
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo university hospital
Study officials:
affiliation: Cairo University
name: Karima A Hassan
role: STUDY_DIRECTOR
References:
citation: Duff WRD, Andrushko JW, Renshaw DW, Chilibeck PD, Farthing JP, Danielson J, Evans CD. Impact of Pilates Exercise in Multiple Sclerosis: A Randomized Controlled Trial. Int J MS Care. 2018 Mar-Apr;20(2):92-100. doi: 10.7224/1537-2073.2017-066.
citation: Demaneuf T, Aitken Z, Karahalios A, Leong TI, De Livera AM, Jelinek GA, Weiland TJ, Marck CH. Effectiveness of Exercise Interventions for Pain Reduction in People With Multiple Sclerosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Phys Med Rehabil. 2019 Jan;100(1):128-139. doi: 10.1016/j.apmr.2018.08.178. Epub 2018 Sep 19.
Clinical trial NCT00802789: Montelukast in Chronic Asthma
Official title: Montelukast in Chronic Asthma: Non-interventional Study With Montelukast 10 mg
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2008-12-05
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Mild to moderate adult asthmatics (≥18 years of age) insufficiently treated with ICS or ICS + LABA

Brief summary: Treatment of patients insufficiently treated with ICS or ICS + LABA.


Eligibility criteria: Inclusion Criteria:

* Patients Insufficiently Treated With ICS Or ICS + LABA.

Primary outcomes:
measure: Documentation of asthma control via ACT (Asthma Control Test).
timeFrame: 6 months (12 months optional)
Secondary outcomes:
measure: Mini Asthma Quality of Life Questionnaire (Mini AQLQ).
timeFrame: 6 months (12 months optional)
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Virchow JC, Mehta A, Ljungblad L, Mitfessel H; MONICA study group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med. 2010 May;104(5):644-51. doi: 10.1016/j.rmed.2009.11.022. Epub 2009 Dec 23.
Clinical trial NCT06470789: Intervention of Shoulder Blood Flow Restriction Training on Shoulder Joint Pain and Function of Judo Athletes
Official title: Intervention of Shoulder Blood Flow Restriction Training on Shoulder Joint Pain and Function of Judo Athletes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Dislocation
Blood Flow Restriction Training
Lead sponsor: Wuhan Sports University
Sponsor class: OTHER
First posted: 2024-06-24
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To observe the effect of shoulder low load blood flow restriction training on pain, function, strength and joint motion of the subjects with shoulder joint dysfunction.


Eligibility criteria: Inclusion Criteria:

* ① Judo athletes, aged 18-30 years old; ② can cooperate with rehabilitation physiotherapy and training and follow-up, and will not quit the study without reason; The presence of shoulder joint pain and dysfunction; After passing the shoulder function test screening, there are two or more positive tests

Exclusion Criteria:

* External injuries of shoulder joint, including bumps, blows, cuts, burns, contusions, etc., without skin rupture, external blood or subcutaneous bleeding; ② congenital abnormal bone structure; ③ There is inflammation, dislocation of shoulder joint, ligament injury; ④ A history of shoulder joint related surgery within one year; ⑤ Injury or discomfort to other body parts;

Primary outcomes:
measure: Shoulder strength
timeFrame: 6week
measure: Shoulder joint range of motion Angle measurement
timeFrame: 6week
measure: Shoulder VAS score
timeFrame: 6week
measure: Shoulder Constant-Murley scale
timeFrame: 6week
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: YangLiu
state: Hubei
Study officials:
References:
Clinical trial NCT05642689: Evaluation of Fe Absorption From Iron Salt in Milk
Official title: Evaluation of Iron Absorption From Ferric Ammonium Phosphate and Ferric Pyrophosphate From an Instant Milk Drink in Young Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Société des Produits Nestlé (SPN)
Sponsor class: INDUSTRY
Collaborators: name: ETH Zurich (Switzerland)
name: Food and Nutrition Research Institute, Philippines
First posted: 2022-12-08
Enrollment: 40
Sex: ALL
Minimum age (years): 3
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double blind randomized crossover study with two parallel arms
Primary purpose: OTHER

Brief summary: The primary objective was:

* to compare iron absorption in apparently healthy children aged 3-6y from an instant full cream milk drink fortified with ferric pyrophosphate or ferric ammonium phosphate relative to ferrous sulfate as the reference fortificant.
* To compare iron absorption from ferric pyrophosphate to ferric ammonium phosphate from the milk drink


Eligibility criteria: Inclusion Criteria:

* 3-6 years old (inclusive)
* Normal BMI for age (WHO standard)
* Apparently healthy, no metabolic or gastrointestinal disorder
* Non-anemic (WHO cut-off for respective age
* No medication or vitamin/mineral supplements will be consumed during the study
* Intake of Vitamin/mineral supplements will be discontinued 2 weeks before the start of the study
* Parents demonstrate an understanding of the given information and ability to comply with the study procedure
* Having obtained his/her parents or his/her legal representative's informed consent

Exclusion Criteria:

* With known gastrointestinal or metabolic disorder or experiencing significant blood losses over the past 6 months
* Possible to have medication during the study
* Currently participating or having participated another clinical trial during the past 3 months prior the beginning of this study
* Subject who cannot be expected to comply with treatment

Primary outcomes:
measure: Determination of iron absorption from FAP and from ferric pyrophosphate relative to Ferrous sulfate
timeFrame: 14 days post isotope consumption
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Walczyk T, Kastenmayer P, Storcksdieck Genannt Bonsmann S, Zeder C, Grathwohl D, Hurrell RF. Ferrous ammonium phosphate (FeNH(4)PO(4)) as a new food fortificant: iron bioavailability compared to ferrous sulfate and ferric pyrophosphate from an instant milk drink. Eur J Nutr. 2013 Jun;52(4):1361-8. doi: 10.1007/s00394-012-0445-y. Epub 2012 Sep 6.
Clinical trial NCT05309889: A Prospective Observational Study of Sepsis
Official title: A Prospective Observational Study of Clinical Efficacy, Complications, and Prognosis in Patients With Sepsis in ICU
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sepsis
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2022-04-04
Enrollment: 174
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were hospitalized in the ICU of Sun Yat-sen Memorial Hospital of Sun Yat-sen University and met the Sepsis 3 diagnostic criteria.

Brief summary: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and is associated with high morbidity and mortality. Sepsis3 gives sepsis a broad definition, reflecting the heterogeneity of the disease. So we need a precise treatment with a stratification of patient prognosis in order to reduce mortality in patients with sepsis.


Eligibility criteria: Inclusion Criteria:

* Patients who met the Sepsis3 diagnostic criteria.

Exclusion Criteria:

* Absence of laboratory test items (blood routine examination, coagulation function, liver function, biochemistry, urine routine examination, urine renal function, urine protein, etc.) \>20%.
* Admission in ICU less than 48 hours.
* Patient with psychiatric disorders.
* Under 18 years of age.

Primary outcomes:
measure: mortality rate
timeFrame: 28 days after diagnosis of sepsis
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study officials:
References: